Arzerra(R) Second Quarter 2013 Net Sales Figures
*Worldwide net sales of Arzerra(r) in Q2 2013 totaled GBP 17.8 million
*Genmab expects royalty payment of DKK 31 million
COPENHAGEN, Denmark, July 24, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that the Arzerra (ofatumumab) net sales
during the second quarter of 2013 were GBP 17.8 million (approximately DKK 156
million). This figure consists of net sales in the U.S. of GBP 10.6 million
and in the rest of the world of GBP 7.2 million. Under the terms of the
collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty
payment of approximately DKK 31 million.
The rest of world sales for the second quarter were enhanced by sales related
to the supply of ofatumumab for clinical trials run by other companies.
The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the second quarter of 2013 (GBP 1.00 = DKK 8.7624).
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
T: +45 33 44 77 20; M: +45 25 12 62 60; E: firstname.lastname@example.org
This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com . Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab^(r); the
Y-shaped Genmab logo^(r); the DuoBody(tm) logo; HuMax^(r); HuMax-CD20^(r);
DuoBody^(r), HexaBody^TM and UniBody^(r). Arzerra^(r) is a registered
trademark of GlaxoSmithKline.
Company Announcement no. 33
CVR no. 2102 3884
1260 Copenhagen K
Press spacebar to pause and continue. Press esc to stop.